David H. Roman

The outlook for smaller players in the Medical Devices segment was becoming difficult, Goldman Sachs’ David H. Roman said in a report. He downgraded the rating for Globus Medical Inc (NYSE: GMED) from Neutral to Sell, while reducing the price target from $26 to $21. A tougher competitive...

Abbott Laboratories (NYSE: ABT) shares have appreciated 7.21 percent over the last month, from a share price of $40.91 on October 13. Goldman Sachs’ David H. Roman has downgraded the rating on the company from Buy to Neutral, while maintaining a price target of $48. Roman explained...

In a report published Monday, Goldman Sachs analyst David H. Roman downgraded the rating on Baxter International (NYSE: BAX) from Conviction List-Buy to Buy, and lowered the price target from $83.00 to $77.00. In the report, Goldman Sachs noted, “We are removing shares of Baxter International (BAX...

In a report published Wednesday, Goldman Sachs analyst David H. Roman upgraded the rating on C.R. Bard (NYSE: BCR) from Sell to Neutral, and raised the price target from $106.00 to $132.00. In the report, Goldman Sachs noted, “We upgrade shares of C.R. Bard (BCR) from Sell to Neutral. Simply put,...

In a report published Monday, Goldman Sachs analyst David H. Roman downgraded the rating on NuVasive (NASDAQ: NUVA) from Neutral to Sell, and lowered the price target from $25.00 to $22.00. In the report, Goldman Sachs noted, “We downgrade NuVasive shares (NUVA) to Sell from Neutral and lower our...

In a report published Monday, Goldman Sachs analyst David H. Roman downgraded the rating on Globus Medical (NYSE: GMED) from Buy to Neutral, and lowered the price target from $19.00 to $18.00. In the report, Goldman Sachs noted, “We downgrade shares of Globus Medical, Inc. (GMED) to Neutral from...

In a report published Monday, Goldman Sachs analyst David H. Roman upgraded the rating on Thoratec Corporation (NASDAQ: THOR) from Neutral to Buy, and raised the price target from $40.00 to $46.00. In the report, Goldman Sachs noted, “We are upgrading shares of Thoratec Corp. (THOR) to Buy from...

In a report published Monday, Goldman Sachs analyst David H. Roman upgraded the rating on Zeltiq Aesthetics (NASDAQ: ZLTQ) from Neutral to Buy, and raised the price target from $8.40 to $12.00. In the report, Goldman Sachs noted, “We are upgrading shares of ZELTIQ Aesthetics, Inc. (ZLTQ) to Buy...

In a report published on Tuesday, Goldman Sachs analyst David H. Roman downgraded Intuitive Surgical (NASDAQ: IRSG) to Neutral and lowered the price target to $500 from $676. In the report, Goldman Sachs noted, "While procedure volumes were somewhat better than most had feared (no material...

In a report published on Tuesday, Goldman Sachs analyst David H. Roman downgraded Hill- Rom Holdings (NYSE: HRC) from Conviction Buy to Neutral and reduced the price target from $38 to $36. In the report, Goldman Sachs noted, "US hospital capex looks to be in a holding pattern, as customers...

In a report published on Wednesday, Goldman Sachs analyst David H. Roman suspended its prior rating and price target on Covidien (NYSE: COV) and announced a new price target of $64 and a Neutral rating on the "new" Covidien which excludes the Mallinckrodt department. In the report, Goldman...

In a report published Monday, Goldman Sachs analyst David H. Roman reiterated a Buy rating and $84.00 price target on Edwards Lifesciences (NYSE: EW). In the report, Goldman Sachs noted, “We have undertaken a detailed review of our thesis on Edwards in light of the stock's ytd underperformance...

In a report published Sunday, Goldman Sachs analyst David H. Roman upgraded the rating on Abbott Laboratories (NYSE: ABT) from Neutral to Buy and raised the price target on the company from $38.00 to $44.00. In the report, Goldman Sachs noted, "(1) Emerging markets growth is taking hold faster...

In a report published Sunday, Goldman Sachs analyst David H. Roman downgraded Thoratec (NASDAQ: THOR) from Buy to Neutral and lowered the price target from $42 to $37. In the report, Goldman Sachs noted that, "...we no longer see significant upside potential to Street numbers. Going forward, we...